We’re excited to share that Biocytogen will be attending BPD’s 7th Annual Cell and Gene Therapy (CGT) Symposium & Vendor Show. The CGT industry in North Carolina is thriving as more companies are choosing to locate their biomanufacturing operations there. This is a fantastic opportunity to learn about the latest technical advances and regulatory revisions changing the landscape of the field.
What is BPD?
Biomanufacturing and Process Development (BPD) serves as a forum for process development and manufacturing scientists and engineers to share the latest developments in bioprocessing. They host several annual events, including conferences, workshops, and roundtables, that feature expert speakers from both industry and academia. Their goal is to drive the industry forward by bridging the gap between innovation and implementation.
Event Overview
Date: April 24th, 2026
Venue: The Friday Conference Center, 100 Friday Center Dr, Chapel Hill, NC 27517
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to connecting in Chapel Hill, NC!
